EEF1A1 and cancer: It was shown that overexpression of a negative dominant mutant, an Ala399 → Val (A399V) of eEF1A, reduced the sensitivity of cancer cells to didemnin B (40), as well as SARS-CoV-2 to plitidepsin by a factor >10 (26).